Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

# Lyttle et al. with support of the PERUKI Collaborative



## **STUDY DESIGN**

### POPULATION

#### • Multi-Center

- Randomized
- Open-label
- Prospective

## Included


- 6 months to 18 years-old
- Convulsive Status
  Epilepticus resistant to benzodiazepines

### Excluded

- Other seizures:
- Pregnancy
- Contraindication/ allergy to
- levetiracetam or phenytoin
- Prior enrollment
- Received 2nd line AED prior to enrollment
- Renal failure

#### **INTERVENTION 1**

Levetiracetam 40 mg/kg IV administered over 5 min. Max dose 2.5 g. No max rate.



## **INTERVENTION 2**

Phenytoin 20 mg/kg IV over *at least* 20 min. Max dose 2 g. Max rate 1 mg/kg/min.



Levetiracetam

Phenytoin

	(n=149)	(n=134)
1 Time to Seizure Control Time to cessation of convulsive act No visible signs of convulsive a Judged by treating physician	551111	45 min
2 Need for further anticonvulsants	37.5%	37.3%
RSI to terminate ongoing seizure	30.0%	35.1%
Admission to critical care	63.8%	53.8%
Serious Adverse Event (death, SJS, rash, airway complication, CV instability, extravasation injury, PICU admission, agitation)	h, 54.8%	51.6%
		* represents p<0.05